MCAD deficiency is the most common inherited fatty acid oxidation disorder, caused by autosomal recessive mutations in the ACADM gene, with a US incidence of 1:13,000–1:19,000. It prevents mitochondrial β-oxidation of medium-chain fatty acids, leading to inability to generate ketone bodies when glycogen stores are depleted. The hallmark presentation is hypoketotic hypoglycemia triggered by fasting or intercurrent illness, which can rapidly progress to seizures, coma, and death if untreated. [1-2]
1. History
- Key HPI questions: Duration of fasting, last oral intake, presence of intercurrent illness (gastroenteritis, URI), vomiting/diarrhea frequency, feeding tolerance
- Symptom characterization: Vomiting, irritability, lethargy, poor feeding, altered mental status
- Timing/triggers: Symptoms classically appear between 2 months and 2 years of age during routine childhood illness (especially gastroenteritis) or during weaning from nighttime feedings [1]
- Progression: Can escalate from lethargy → seizures → coma → death within hours if glucose is not provided
- Important negatives: Absence of ketones in urine despite hypoglycemia is a critical diagnostic clue (hypoketotic hypoglycemia) [3]
2. Alarm Features
- Altered mental status, seizures, or coma — indicates severe hypoglycemia requiring immediate IV dextrose [1]
- Respiratory arrest, apnea, cardiac arrhythmia [4-5]
- Hepatomegaly with acute liver failure (Reye-like presentation) [3][6]
- Hyperammonemia
- Any infant or child with unexplained sudden death — MCADD should be considered in post-mortem workup [7]
- Before newborn screening, up to 18% of patients had a fatal outcome with their first metabolic crisis [1]
3. Medications
- Contraindicated/avoid:
- Valproic acid — inhibits fatty acid oxidation [3]
- NSAIDs and salicylates — inhibit FAO and risk Reye-like syndrome [3]
- IV lipid emulsions — avoid during acute decompensation [3]
- Triheptanoin — contraindicated in MCAD deficiency (requires MCAD for metabolism) [8]
- Treatments:
- L-carnitine 25–100 mg/kg/day orally (controversial; some centers supplement only when levels are low) [1-2]
- Antipyretics (acetaminophen preferred over NSAIDs) for fever management
- Pearl: If the patient has a metabolic emergency letter, follow its carnitine guidance. If unavailable, contact the metabolic specialist [1]
4. Diet
- Fasting avoidance is the cornerstone of management: [2]
- Birth–4 months: no more than 4 hours fasting
- 5–12 months: add 1 hour per month of age (e.g., 5 hours at 5 months, up to 12 hours at 12 months)
- Age >1 year: no fasting >12 hours for life
- Normal healthy diet with no more than 30% of total energy from fat [2]
- Bedtime snack or 2 g/kg uncooked cornstarch as a complex carbohydrate source to maintain overnight glucose [2]
- Avoid MCT oil and MCT-containing formulas (coconut oil, MCT-supplemented formulas) [2]
- During illness: push simple carbohydrates (juice, glucose tablets, sweetened non-diet beverages)
- Long-term concern: Frequent feeding regimens predispose to obesity — regular nutritional counseling is essential [2]
5. Review of Systems
- Neuro: Lethargy, irritability, seizures, developmental delay, ADHD (long-term sequelae)
- GI: Vomiting, diarrhea, poor feeding, hepatomegaly
- Cardiac: Arrhythmias (especially neonatal period) [4]
- MSK: Chronic muscle weakness/myopathy (after uncontrolled decompensation) [2]
- Growth: Typically normal growth; monitor for obesity from treatment-related overfeeding [2][4]
6. Collateral History and Family History
- Autosomal recessive inheritance — ask about consanguinity, Northern European ancestry (founder effect for c.985A>G variant) [5]
- History of unexplained sibling death or SIDS — a critical red flag for undiagnosed MCADD [9]
- Previous episodes of unexplained lethargy, hypoglycemia, or acidosis in the patient or siblings
- Maternal history: undiagnosed maternal MCADD or carnitine transporter deficiency can cause false-negative newborn screens [2]
7. Risk Factors
- Northern European descent — highest carrier frequency [5]
- Homozygosity for the common c.985A>G (p.Lys329Glu) variant — associated with more severe biochemical phenotype and more hypoglycemic events [4][10]
- Prolonged fasting — the single most important modifiable risk factor [1]
- Intercurrent febrile illness (especially gastroenteritis with vomiting/diarrhea) [1]
- Breastfed neonates may have higher initial octanoylcarnitine levels and are at risk during establishment of feeding [11]
- Weaning from nighttime feedings [1]
8. Differential Diagnosis
- Reye syndrome — historically confused with MCADD; differentiated by aspirin exposure, mitochondrial changes on liver biopsy, and absence of characteristic acylcarnitine profile [6][9]
- Other fatty acid oxidation disorders: VLCAD deficiency, LCHAD deficiency (distinguish by acylcarnitine chain length pattern; long-chain FAODs also cause cardiomyopathy and rhabdomyolysis) [9]
- Multiple acyl-CoA dehydrogenase deficiency (MADD/glutaric aciduria type II) — broader acylcarnitine elevations across multiple chain lengths [12]
- Glycogen storage diseases — hepatomegaly and hypoglycemia but typically ketotic [13]
- Hyperinsulinism — hypoglycemia but with suppressed ketones AND suppressed free fatty acids (unlike MCADD where FFAs are elevated)
- Sepsis/meningitis — can mimic with lethargy, vomiting, altered mental status
- Non-accidental trauma — unexplained encephalopathy in an infant
9. Past Medical History
- Newborn screening result — most patients now identified presymptomatically [1]
- Previous metabolic crises, ER visits, or hospitalizations for hypoglycemia [4]
- History of developmental delay, ADHD, or speech delay (sequelae of prior decompensation) [2]
- Surgical history — any procedure requiring fasting is high-risk and requires perioperative glucose management [1-2]
10. Physical Exam
- Vital signs: Tachycardia, hypothermia (late sign of metabolic crisis), fever (if intercurrent illness)
- Neuro: Altered mental status ranging from irritability to lethargy to coma; seizure activity
- Abdomen: Hepatomegaly during acute decompensation [9]
- General: Diaphoresis, poor tone, pallor
- Between episodes: Exam is typically completely normal — this is a key feature [6]
- Growth: Normal growth expected; monitor BMI for treatment-related obesity [4]
11. Lab Studies
- Point-of-care glucose — obtain immediately; hypoglycemia (<70 mg/dL, often <40 mg/dL) is the critical finding [1]
- Plasma acylcarnitine profile — elevated C8 (octanoylcarnitine) with lesser elevations of C6, C10, C10:1; elevated C8/C10 ratio >5 and elevated C8/C2 ratio [2][12]
- Urine organic acids — elevated medium-chain dicarboxylic acids (hexanoylglycine > octanoylglycine > decanoylglycine), suberylglycine [2]
- Serum ketones/beta-hydroxybutyrate — inappropriately low relative to degree of hypoglycemia (hypoketotic) [2]
- Free and total carnitine levels — may show secondary carnitine deficiency [2]
- CMP: Elevated AST/ALT during decompensation; hyperammonemia may occur [3-4]
- CBC, blood gas — metabolic acidosis possible during crisis [3]
- Pearl: Obtain screening labs before starting glucose, as biochemical markers normalize rapidly with treatment [3]
12. Imaging
- Not routinely required for diagnosis or acute management
- Brain MRI — indicated if concern for neurologic sequelae from prior hypoglycemic episodes (may show basal ganglia or cortical injury)
- Liver ultrasound — may show hepatic steatosis or hepatomegaly during acute episodes [9]
- Echocardiogram — consider if cardiac arrhythmia or concern for cardiomyopathy (more relevant for long-chain FAODs, but cardiac arrhythmias have been reported in neonatal MCADD) [4]
13. Special Tests
- Tandem mass spectrometry (MS/MS) — the basis of newborn screening; detects elevated C8-acylcarnitine on dried blood spot [2][12]
- Urine acylglycine analysis — hexanoylglycine elevation is highly specific [2]
- Molecular genetic testing — ACADM gene sequencing; the c.985A>G (p.Lys329Glu) variant accounts for ~81% of alleles in clinically identified patients [2][5]
- MCAD enzyme activity assay — in cultured fibroblasts or lymphocytes; available only at specialized centers [2]
- Diagnostic criteria for acylcarnitine analysis: C8 >0.3 µmol/L, C8/C10 ratio >5, no elevated species >C10 [12]
14. ECG
- Obtain ECG if neonatal presentation or any concern for cardiac arrhythmia [4]
- Cardiac arrhythmias (including cardiac arrest) have been reported, particularly in neonates [4-5]
- No specific ECG pattern is pathognomonic; monitor for QTc prolongation and arrhythmias during acute metabolic crisis
15. Assessment
- MCADD is a treatable and preventable cause of metabolic crisis when identified early through newborn screening [1]
- Severity stratification: Homozygotes for c.985A>G have higher C8 levels, more hypoglycemic events, and higher transaminases compared to compound heterozygotes [4]
- Typical presentation: Well-appearing infant/toddler who develops lethargy and vomiting during a routine illness after a period of poor oral intake
- Atypical presentations: Neonatal crisis in the first week of life (before NBS results available), adult-onset presentation (rare), sudden unexpected death [6-7]
- Complications: Brain damage from prolonged hypoglycemia, developmental delay, ADHD, chronic myopathy, hepatic steatosis, death [2][6]
16. Treatment Plan
Acute stabilization (ED/inpatient)
- Immediate IV glucose: 10% dextrose with appropriate electrolytes at 1.5× maintenance rate (glucose infusion rate 10–12 mg/kg/min) to achieve and maintain blood glucose >100–120 mg/dL [1-3]
- For severe hypoglycemia with altered mental status: D10W bolus 2–5 mL/kg followed by continuous infusion [1]
- Correct electrolyte and pH imbalances [2]
- Avoid: IV lipids, valproic acid, NSAIDs, salicylates [3]
- Treat the underlying trigger (antibiotics for infection, antiemetics, etc.)
- Continue home L-carnitine regimen if applicable; contact metabolic specialist for guidance [1]
- Do not reduce IV glucose rate to encourage oral intake until the child has demonstrated substantial improvement and is tolerating ~75% of typical home intake [1]
Chronic/outpatient management
- Strict fasting avoidance per age-based guidelines [2]
- Diet: ≤30% calories from fat, bedtime cornstarch or snack [2]
- L-carnitine supplementation: 25–50 mg/kg/day if secondary deficiency present (practice varies by center) [2]
- MedicAlert bracelet and emergency letter from metabolic specialist [2]
- Metabolic dietitian involvement [2]
17. Disposition
- Admit if: hypoglycemia on presentation, altered mental status, inability to tolerate oral intake, ongoing vomiting/diarrhea, or any concern for metabolic decompensation [1]
- Observation (minimum overnight) is recommended even if initial labs are reassuring — the AAP emphasizes that patients require immediate triage and should not be made to wait [1-2]
- Discharge criteria: Tolerating ~75% of typical oral intake without emesis, normoglycemia maintained off IV dextrose, underlying illness improving [1]
- Specialist consultation: Contact the patient's metabolic specialist for every ED visit, even if the evaluation is negative and the patient appears well [1]
18. Follow Up / Return Precautions
- Follow-up: Establish care with biochemical genetics clinic within 2–3 months of diagnosis, then every 6–12 months if clinically well [2]
- Return immediately if:
- Vomiting >2 times or inability to keep fluids down
- Lethargy, excessive sleepiness, or difficulty waking
- Temperature >38.5°C with poor oral intake [2]
- Seizure activity or any change in mental status
- New neurologic symptoms [2]
- Counseling points:
- Always carry the emergency letter; share with schools, daycares, and babysitters [2]
- Push simple carbohydrates early in any illness — do not wait for symptoms
- Contact metabolic center before any planned surgery or dental procedure requiring fasting [2]
- Expected recovery: With early identification and fasting avoidance, no irreversible complications were observed after diagnosis in one longitudinal cohort [4]
- Surveillance: Monitor growth, developmental milestones, neurobehavioral issues, and carnitine levels at routine visits [2]
Images
References
1. Management Principles for Acute Illness in Patients With Medium-Chain Acyl-Coenzyme a Dehydrogenase Deficiency. — McGregor TL, Berry SA, Dipple KM, Hamid R. Pediatrics. 2021.
2. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. — Chang IJ, Lam C, Vockley J GeneReviews® [Internet]. 2024.
3. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Diagnosis and Management of Pediatric Acute Liver Failure. — Squires JE, Alonso EM, Ibrahim SH, et al. Journal of Pediatric Gastroenterology and Nutrition. 2022.
4. Clinical and Biochemical Outcomes of Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency. — Anderson DR, Viau K, Botto LD, Pasquali M, Longo N. Molecular Genetics and Metabolism. 2020.
5. Medium Chain Acyl-CoA Dehydrogenase Deficiency Human Genome Epidemiology Review. — Wang SS, Fernhoff PM, Hannon WH, Khoury MJ. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2001.
6. Medium-chain acyl-CoA dehydrogenase deficiency. — National Library of Medicine (MedlinePlus) 2015.
7. Sudden Neonatal Death in Individuals With Medium-Chain Acyl-Coenzyme a Dehydrogenase Deficiency: Limit of Newborn Screening. — Mütze U, Nennstiel U, Odenwald B, et al. European Journal of Pediatrics. 2022.
8. Heptanoic and Medium Branched-Chain Fatty Acids as Anaplerotic Treatment for Medium Chain Acyl-CoA Dehydrogenase Deficiency. — Karunanidhi A, Basu S, Zhao XJ, et al. Molecular Genetics and Metabolism. 2023.
9. Medium-Chain and Long-Chain Acyl CoA Dehydrogenase Deficiency: Clinical, Pathologic and Ultrastructural Differentiation From Reye's Syndrome. — Treem WR, Witzleben CA, Piccoli DA, et al. Hepatology. 1986.
10. Free carnitine concentrations and biochemical parameters in medium‐chain acyl‐CoA dehydrogenase deficiency: Genotype–phenotype correlation. — Weiss KJ, Berger U, Haider M, et al. Clinical Genetics. 2023.
11. Spectrum of Medium-Chain Acyl-CoA Dehydrogenase Deficiency Detected by Newborn Screening. — Hsu HW, Zytkovicz TH, Comeau AM, et al. Pediatrics. 2008.
12. Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: Diagnosis by Acylcarnitine Analysis in Blood. — Van Hove JL, Zhang W, Kahler SG, et al. American Journal of Human Genetics. 1993.
13. AASLD Practice Statement on the Evaluation and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Children. — Xanthakos SA, Ibrahim SH, Adams K, et al. Hepatology. 2025.